Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 15/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828108 | 0.92 | HTR1A (0.58) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL4820337 | 0.91 | HTR1A (0.57) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL6628132 | 0.87 | HTR1A (0.52) | HTR1ASLC6A4MAPK1 | |
| SCHEMBL6629580 | 0.87 | HTR1A (0.61) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL6796362 | 0.86 | HTR1A (0.49) | HTR1ASLC6A4MAPK1 | |
| SCHEMBL4820939 | 0.85 | HTR1A (0.57) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL4827109 | 0.84 | HTR1A (0.58) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL6767230 | 0.84 | HTR1A (0.50) | HTR1ASLC6A4MAPK1 | |
| SCHEMBL6629339 | 0.81 | HTR1A (0.53) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL6630467 | 0.81 | HTR1A (0.81) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392697-B1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO 2,3-F]QUINOLINE | WYETH CORP (US) | 2004-11-03 | — | — | EP | claimed |
| EP-1392697-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO 2,3-F]QUINOLINE | Wyeth (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030045542-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline | WYETH | 2003-03-06 | — | — | US | claimed |
| US-20020165245-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE | WYETH | 2002-11-07 | — | — | US | claimed |
| US-6458802-B1 | ANTIDEPRESSANTS, OBSESSIVE COMPULSIVE DISORDER, DIETETICS | WYETH | 2002-10-01 | — | — | US | claimed |
| WO-2002072587-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE | WYETH (US) | 2002-09-19 | — | — | WO | claimed |
| EP-1392697-B1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO 2,3-F]QUINOLINE | WYETH CORP (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1392697-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO 2,3-F]QUINOLINE | Wyeth (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6599915-B2 | 5HT1A antagonist limit the negative feedback of autoceptors seen with serotonic reuptake inhibitors | WYETH | 2003-07-29 | — | — | US | disclosed |
| US-20030045542-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline | WYETH | 2003-03-06 | — | — | US | disclosed |
| US-20020165245-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE | WYETH | 2002-11-07 | — | — | US | disclosed |
| US-6458802-B1 | ANTIDEPRESSANTS, OBSESSIVE COMPULSIVE DISORDER, DIETETICS | WYETH | 2002-10-01 | — | — | US | disclosed |
| WO-2002072587-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE | WYETH (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045542-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline | CYP19A1, DDT, DRD2 | HTR1A 57/4885SLC6A4 107/4885CYP3A4 174/4885 |
| US-20020165245-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE | CYP19A1, DBH, DDT | HTR1A 52/4885SLC6A4 106/4885CYP3A4 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.